Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Cyprote acetate (Prostate)
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cyproterone 50mg tablets
0803042E0AAAAAA
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | 7,813 |
|
Cyproterone 100mg tablets
0803042E0AAABAB
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | 1,308 |
|
Cyproterone 100mg/5ml oral liquid
0803042E0AAADAD
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | No data available |
|
Cyproterone 150mg/5ml oral liquid
0803042E0AAAHAH
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | No data available |
|
Cyproterone 25mg/5ml oral liquid
0803042E0AAAEAE
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | No data available |
|
Cyproterone 2mg/5ml oral suspension
0803042E0AAAIAI
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | No data available |
|
Cyproterone 50mg/5ml oral suspension
0803042E0AAAFAF
|
Cyprote acetate (Prostate) | Cyproterone acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.